Russell Beyer's Insider Trades & SAST Disclosures
Russell Beyer's most recent trade in SAB Biotherapeutics Inc was a trade of 275,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 14, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Russell Beyer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 275,000 | 275,000 | - | - | Employee Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Russell Beyer | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2022 | 274,875 | 274,875 | - | - | Employee Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.10 per share. | 18 Oct 2021 | 2,475 | 2,475 | - | 10.1 | 24,998 | Common Stock |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.90 per share. | 18 Oct 2021 | 278 | 0 | - | 7.9 | 2,196 | Common Stock |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.08 per share. | 18 Oct 2021 | 149 | 149 | - | 10.1 | 1,502 | Common Stock |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 7.78 per share. | 18 Oct 2021 | 129 | 278 | - | 7.8 | 1,004 | Common Stock |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.10 per share. | 18 Oct 2021 | 10 | 15 | - | 10.1 | 101 | Common Stock |
| SAB Biotherapeutics Inc | Russell Beyer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 18 Oct 2021 | 5 | 5 | - | 10 | 50 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges